Literature DB >> 34923693

A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study.

E Sotiriou1, K Bakirtzi1, I Papadimitriou1, A Tsentemeidou1, P Eftychidou1, V Eleftheriadis1, A Lallas1, D Ioannides1, E Vakirlis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34923693     DOI： 10.1111/jdv.17880

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  2 in total

1.  [Erythrodermic psoriasis after COVID-19].

Authors:  Jeta Demiri; Miriam Abdo; Athanasios Tsianakas
Journal:  Hautarzt       Date:  2021-12-14       Impact factor: 0.751

Review 2.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.